As the generation of TMAO depends on oxidation by hepatic flavin-containing monooxygenase (FMO3), the improved hepatic steatosis seen after RYGB surgery might result in restored hepatic function and FMO3 activation. This evidence concerns the gene FMO3 and fatty liver disease.